Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn who retired from the company in December.
Related news for (CINGW)
- Cingulate Announces Closing of $7.5 Million Public Offering
- Cingulate Announces Pricing of $7.5 Million Public Offering
- Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
- Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)